ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Astellas buys into Frequency’s hearing-loss drug

by Lisa M. Jarvis
July 19, 2019 | APPEARED IN VOLUME 97, ISSUE 29

Astellas Pharma will pay Frequency Therapeutics $80 million up front for access to the hearing-loss treatment FX-322. Frequency’s combination of small-molecule drugs is injected into the middle ear, where it can induce regeneration of sensory receptors called hair cells. Astellas will lead development of FX-322 outside the US, while Frequency will be responsible for clinical studies in the US, where it plans to begin a Phase IIa trial late this year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment